Table 1 Clinical features of B-ALL pediatric patients enrolled for the analysis of TEX41 expression
| PATIENT ID | Pt 1 | Pt 2 | Pt 3 | Pt 4 | Pt 5 | Pt 6 | Pt 7 | Pt 8 | Pt 9 | Pt 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 3,6 | 4,5 | 2,9 | 11,1 | 10,9 | 15 | 10,2 | 9,9 | 14,8 | 4.9 |
| Sex | M | M | F | M | F | F | M | F | M | M |
| Race | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Caucasian | Indian | Caucasian | Caucasian | Caucasian |
| WBC | 67,550/mmc | n.d. | n.d. | 3790/mmc | 4730/mmc | 120,690/mmc | 453,600/mmc | |||
| BM blast(%) | 68 | 80 | 70 | 65 | 89 | 50 | 80 | 90 | 95 | 70 |
| Immuno-phenotype | B common | B common | B common | B common | B common | B common | B common | B common | B common | B common |
| Molecular biology |
t (1;19) E2A/PBX1 rearrangement |
t (12;21) TEL/AML1 rearrangement | Negative | Negative | Negative | Negative | Negative | Negative | Negative |
t (12;21) TEL/AML1 rearrangement |
| Cytogenetic | 45, XY, i (9)(q10), -13, add (19)(p13)[8]/46, XY,[8] | 46,XY | 46,XX | 59, XXXY, + 4,+4,+5,+6, + 10 + 14,+17,18,+21,+21[5]/46, XY, [10] | NE | 46, XX | NE | NE | 46, XY | 46, XY |
| GPR day + 8 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes |
| BM blast < 10 % day + 15 | Yes | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes |
| NCI risk | High | NE | High | High | High | High | High | High | High | High |
| MRD risk | Standard | Intermediate | Intermediate | Standard | Intermediate | NE | NE | NE | NE | NE |
| Tex41 | 0,00048571 | 0,00003693 | 0,00004515 | 0,00120526 | 0,00001881 | 0,00003052 | 0,00001824 | 0,00001256 | 0,00001052 | 0,00107202 |